Lack of Monitoring and Clinical Efficacy Will Be the Key Drivers of Preferred Formulary Placement for Boehringer Ingelheim Corporation ’s Pradaxa

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that lack of monitoring and clinical efficacy will be the key drivers of preferred formulary placement for Boehringer Ingelheim’s Pradaxa, recently approved in the U.S. for stroke prevention in atrial fibrillation. However, 59 percent of office-based cardiologists say its high cost is still an issue, according to new market access findings from Decision Resources.